The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Johnson & Johnson reported first-quarter revenue of $24.1 billion, up about 10% from a year earlier, and raised its full-year 2026 sales and earnings outlook, the company said April 14.

Adjusted earnings per share came in at $2.70 for the quarter, the company said. According to Reuters, that figure exceeded the analyst consensus estimate of $2.66, and the revenue result topped Wall Street expectations of $23.6 billion, according to LSEG data.

The Innovative Medicine segment posted worldwide reported sales of $15.4 billion, up 11.2% from a year earlier, the company said. Growth was driven by cancer therapy Darzalex, which brought in $4.0 billion for the quarter, along with CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in oncology, TREMFYA in immunology, and SPRAVATO in neuroscience. The MedTech segment reported sales of $8.6 billion, up 7.7%.

Revenue from Stelara dropped to $656 million — a roughly 60% decline year over year — as biosimilar rivals have entered the market following the drug's patent expiration, Reuters reported. At its height, Stelara generated more than $10 billion in annual sales. Rather than moving to biosimilar versions, a significant portion of Stelara patients have gravitated toward alternative therapies, CFO Joseph Wolk said. "We are seeing increased share in Tremfya and we anticipate we'll see something similar in the new oral offering," Wolk told Reuters, referring to Icotyde, which received FDA approval in March. Tremfya brought in $1.6 billion for the quarter, the company said.

For full-year 2026, Johnson & Johnson raised its estimated reported sales range to $100.3 billion–$101.3 billion, with a midpoint of $100.8 billion, up from a January guidance midpoint of $100.5 billion. Adjusted EPS guidance was lifted to a range of $11.45–$11.65, with a midpoint of $11.55, compared with $11.53 previously. The company said it does not provide GAAP financial measures on a forward-looking basis.

On a reported GAAP basis, net earnings fell 52.4% to $5.2 billion, compared with $11.0 billion in the first quarter of 2025, the company said.

"Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact," CEO Joaquin Duato said in a statement.

As part of a broader set of most-favored-nation pricing agreements between major pharmaceutical companies and the Trump administration, J&J is committed to bringing its U.S. drug prices down to levels comparable to those in other wealthy nations, with tariff relief offered in return. Wolk said the company opposes efforts to make those deals permanent through legislation. "We're not a fan of codifying" most-favored-nation pricing, he told Reuters. "It's really kind of a back door to price controls."

J&J also announced during the quarter a commitment of more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania, the company said.